Identifying an optimal fludarabine exposure for improved outcomes after axi-cel therapy for aggressive B-cell non-Hodgkin lymphoma

Fludarabine is one of the most common agents given for lymphodepletion before CD19 chimeric antigen receptor T cells, but its optimal therapeutic intensity is unknown. Using data from a multicenter consortium, we estimated fludarabine exposure (area under the curve [AUC]) using a population pharmaco...

Descripción completa

Detalles Bibliográficos
Autores principales: Scordo, Michael, Flynn, Jessica R., Gonen, Mithat, Devlin, Sean M., Parascondola, Allison, Tomas, Ana Alarcon, Shouval, Roni, Brower, Jamie, Porter, David L., Schuster, Stephen J., Bachanova, Veronika, Maakaron, Joseph, Maziarz, Richard T., Chen, Andy I., Nastoupil, Loretta J., McGuirk, Joseph P., Oluwole, Olalekan O., Ip, Andrew, Leslie, Lori A., Bishop, Michael R., Riedell, Peter A., Perales, Miguel-Angel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10514205/
https://www.ncbi.nlm.nih.gov/pubmed/37522731
http://dx.doi.org/10.1182/bloodadvances.2023010302

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10514205/
https://www.ncbi.nlm.nih.gov/pubmed/37522731
http://dx.doi.org/10.1182/bloodadvances.2023010302

Ejemplares similares